UBS Group Boosts Pfizer (NYSE:PFE) Price Target to $25.00

Pfizer (NYSE:PFE - Get Free Report) had its price target increased by stock analysts at UBS Group from $24.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's target price indicates a potential upside of 3.41% from the company's previous close.

Several other research analysts also recently weighed in on the stock. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $29.64.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.39 during mid-day trading on Wednesday, hitting $24.18. The company had a trading volume of 11,474,420 shares, compared to its average volume of 48,005,016. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's 50 day simple moving average is $24.48 and its two-hundred day simple moving average is $25.86. The stock has a market cap of $137.11 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pfizer

Hedge funds have recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $28,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.